Hypoglycaemia

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
GLP-1N/A1 trial
Active Trials
NCT01347801Completed40Est. Sep 2014
UNEEG Medical
UNEEG MedicalDenmark - Allerod
1 program
Insulin clampN/A1 trial
Active Trials
NCT01337362Completed23Est. Jun 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UNEEG MedicalInsulin clamp
Novo NordiskGLP-1

Clinical Trials (2)

Total enrollment: 63 patients across 2 trials

NCT01337362UNEEG MedicalInsulin clamp

Recurrent Hypoglycaemia in Type 1 Diabetes

Start: May 2011Est. completion: Jun 201323 patients
N/ACompleted
NCT01347801Novo NordiskGLP-1

Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1

Start: Mar 2011Est. completion: Sep 201440 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space